ValuEngine upgraded shares of Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) from a sell rating to a hold rating in a research note released on Friday.
A number of other research firms have also recently weighed in on TRIL. Zacks Investment Research cut shares of Trillium Therapeutics from a hold rating to a sell rating in a research report on Friday, September 1st. HC Wainwright set a $7.00 price objective on shares of Trillium Therapeutics and gave the company a buy rating in a research report on Monday, August 14th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Trillium Therapeutics presently has a consensus rating of Buy and a consensus price target of $12.33.
Trillium Therapeutics (NASDAQ TRIL) opened at $10.10 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.33 and a quick ratio of 6.33. Trillium Therapeutics has a 12-month low of $4.15 and a 12-month high of $13.30.
A number of large investors have recently bought and sold shares of the business. Creative Planning boosted its position in Trillium Therapeutics by 1.1% in the 2nd quarter. Creative Planning now owns 26,400 shares of the biotechnology company’s stock valued at $116,000 after buying an additional 300 shares during the last quarter. Virtu KCG Holdings LLC purchased a new position in Trillium Therapeutics in the 2nd quarter valued at about $128,000. Sectoral Asset Management Inc boosted its position in Trillium Therapeutics by 27.8% in the 3rd quarter. Sectoral Asset Management Inc now owns 234,248 shares of the biotechnology company’s stock valued at $1,206,000 after buying an additional 50,976 shares during the last quarter. K2 Principal Fund L.P. acquired a new stake in shares of Trillium Therapeutics in the 2nd quarter valued at about $264,000. Finally, Victory Capital Management Inc. raised its stake in shares of Trillium Therapeutics by 88.9% in the 2nd quarter. Victory Capital Management Inc. now owns 146,571 shares of the biotechnology company’s stock valued at $645,000 after purchasing an additional 68,970 shares in the last quarter. 47.45% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/05/trillium-therapeutics-tril-upgraded-at-valuengine.html.
About Trillium Therapeutics
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.